Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment

Area of Science:

• Biochemistry
• Enzymology
• Cancer Biology

Background:

• Matrix metalloproteinases (MMPs) are zinc-dependent enzymes involved in extracellular matrix (ECM) remodeling.
• MMP-9, a gelatinase B family member, plays a critical role in cancer pathogenesis and progression.
• Currently, no FDA-approved MMP-9 inhibitors are available for clinical use.

Purpose of the Study:

• To review diverse strategies for designing and advancing MMP-9 inhibitors.
• To evaluate the anticancer effects and selectivity of various MMP-9 inhibitors.
• To identify essential structural characteristics for future MMP-9 inhibitor development.

Main Methods:

• Narrative review of existing literature on MMP-9 inhibitor design.
• Analysis of reported anticancer effects and selectivity profiles.
• Highlighting recently discovered MMP-9 inhibitors with notable potency and selectivity.

Main Results:

• Several strategies for MMP-9 inhibitor design have been explored.
• Recent inhibitors show promising selectivity and potency against MMP-9.
• Understanding structural requirements is key for effective inhibitor development.

Conclusions:

• Targeting MMP-9 is a promising strategy for cancer therapy.
• Further research into selective MMP-9 inhibitors is warranted.
• Novel inhibitors with improved structural characteristics are emerging.